Method of preventive on-demand hormonal contraception

1 . Method of hormonal female controlled on-demand contraception, characterized in that a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.

2 . Method according to claim 1 , characterized in that the pharmaceutical preparation is administered at the latest just prior to the first anticipated intercourse.

3 . Method according to claim 2 , characterized in that the pharmaceutical preparation is administered no earlier than 12 hours prior to intercourse.

4 . Method according to claim 1 , characterized in that the progestogen administered is selected from the group of compounds:

desogestrel,

etonorgestrel,

gestodene,

levonorgestrel or

trimegestone.

5 . Method according to claim 4 , characterized in that the progestogen is released daily in an amount which results in endogenous progestogen levels which are equivalent in effect to endogenous gestodene levels developing after daily transdermal administration of 50 to 100 μg of gestodene.

6 . Method according to claim 5 , characterized in that 50 to 100 μg of gestodene are administered daily.

7 . Method according to claim 1 , characterized in that an estrogen is administered in addition.

8 . Method according to claim 7 , characterized in that the estrogen administered is ethinylestradiol.

9 . Method according to claim 8 , characterized in that the ethinylestradiol is administered in an amount which brings about a daily release of 10 to 30 μg of ethinylestradiol.

10 . Pharmaceutical preparation for use in any of the aforementioned methods according to claim 1 .

11 . Transdermal patch comprising exclusively one, or more progestogens as active substance.

12 . Transdermal patch according to claim 11 comprising gestodene as progestogen.

13 . Transdermal patch according to claim 11 , from which an amount of progestogen equivalent in effect to 50 to 100 μg of gestodene is released.

14 . Transdermal patch according to claim 11 having a size of 10 to 30 cm 2 .

15 . Transdermal patch according to claim 11 , characterized in that the patch has a size of 10 to 20 cm 2 and that 50 to 100 μg of gestodene are released daily.

16 . (canceled)

17 . Pharmaceutical kit comprising at least one transdermal patch comprising one or more progestogens as active substance and optionally one or more estrogens, for carrying out a method according to claim 1 , together with a product information leaflet describing the use of the patch in a method.